glp-1 and dpp-4 inhibitors DPP4 vs Agonists | June 2021 | Clinical Corner The Impact of Dipeptidyl-peptidase 4
Description
J Physiol Sci 69: 143-149, 2019
Firstly, it was conducted within the Veterans Affairs healthcare system, which serves a population that is predominantly older, male, and white, potentially limiting the generalisability of our findings
Programs may include Semaglutide and Tirzepatide
A new review explores how GLP-1 receptor agonists may blunt alcohol and drug reward signals, opening a promising but still unproven path toward repurposed treatments for addiction
This article does not independently verify these credentials
